Abbott Laboratories $ABT Shares Acquired by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 36.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,689 shares of the healthcare product maker’s stock after purchasing an additional 5,269 shares during the period. EverSource Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $2,021,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 2.0%

ABT stock opened at $105.83 on Friday. The company has a fifty day moving average price of $93.08 and a 200 day moving average price of $100.58. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a market cap of $183.12 billion, a price-to-earnings ratio of 34.25, a price-to-earnings-growth ratio of 2.09 and a beta of 0.61. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ABT shares. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Argus cut their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Oppenheimer cut their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Stifel Nicolaus cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Jefferies Financial Group reduced their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott remains a favored income stock among analysts, with TipRanks highlighting its Dividend Aristocrat status and recurring cash distributions. 3 Strong Buy Dividend Aristocrat Stocks to Power Your Cash Flow
• Positive Sentiment: Erste Group Bank raised its fiscal 2026 EPS estimate to $5.52 from $5.47 and nudged its fiscal 2027 estimate to $6.06 from $6.05, broadly confirming consensus expectations.
• Positive Sentiment: UBS issued a Buy rating, while TD Cowen maintained its Buy rating and a $115 price target, citing a strengthening nutrition franchise and additional 2026 growth drivers. UBS Issues a Buy Rating on Abbott Laboratories Abbott Laboratories Buy Rating Backed by Growth Drivers
• Positive Sentiment: Abbott recently exceeded quarterly EPS and revenue expectations, with revenue growth of 13% year over year, supporting the case for continued earnings momentum.
• Neutral Sentiment: Abbott has begun a roughly 1,000-patient real-world TriClip study to evaluate safety and performance in heart-valve repair. The study could strengthen the product’s positioning, but it also underscores intensifying competition from Edwards. Abbott Starts TriClip Study Amid Rising Competition
• Negative Sentiment: UBS has lowered its expectations for Abbott’s stock price, creating a counterweight to the Buy rating and other positive analyst revisions. The conflicting views may be contributing to investor caution.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.